Glenmark Pharmaceuticals Recalls 1,200 Bottles Of Hypertension Drug In US

New Delhi : Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).

The New Jersey-based arm of the drug firm is recalling 1,200 bottles of Trandolapril and Verapamil Hydrochloride extended-release tablets, Batch # 19224744 as per the latest Enforcement Report of the US health regulator.

The affected lot has been manufactured at the Goa plant of the Mumbai-based drug firm and then supplied to Glenmark Pharmaceuticals Inc, USA, the USFDA said.

The firm is recalling the affected bottles due to it being “Subpotent”, it noted.

Subpotent means ‘Out of Specification for Assay Test at the 3-month time point.’

Glenmark Pharmaceuticals Inc initiated the nationwide (US) Class III recall on August 14 this year, it added.

As per the USFDA, a Class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.

Related Posts

Licences of 20 medical stores suspended after inspections

Drug Control Department inspects 120 medical stores; 32 NDPS cases and 63 arrests recorded in 2026 so far The district administration has intensified action against illegal drug sale and distribution,…

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

NEW DELHI: Global investment firm Bain Capital has divested nearly a 1 per cent stake in Emcure Pharmaceuticals for over Rs 289 crore through open market transactions, according to the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert

Civil society group SAM calls for greater transparency involving clinical trials

Civil society group SAM calls for greater transparency involving clinical trials

Different packaging, typos expose fake Mounjaro racket

Different packaging, typos expose fake Mounjaro racket